Insmed nabs new patent for ARIKAYCE in U.S.

Apr. 10, 2019 6:33 AM ETInsmed Incorporated (INSM)By: Mamta Mayani, SA News Editor
  • The USPTO has issued Insmed Incorporated (NASDAQ:INSM), patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension).
  • The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy.
  • This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and second with an expiry date of May 15, 2035.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.